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Aim: This clinical study was undertaken to investigate 
whether F2-isoprostane, a prostaglandin F2-like 
compound derived from the non-enzymatic peroxidation 
of arachidonic acid, could serve as a novel biomarker 
for early detection of type 2 diabetes mellitus (T2DM) 
or its complications. Materials and Methods: 
Twenty-five individuals who had impaired glucose 
tolerance (IGT) or T2DM were compared with controls. 
Anthropometry, plasma glucose, hemoglobin A1c, 
lipid profile and F2-isoprostane levels were measured 
in these subjects. Results: Clinical characteristics 
of subjects with IGT showed significant alteration 
when compared to subjects with T2DM but not with 
that of controls having normal glucose tolerance. 
In the case of isoprostane levels, there existed a 
significant difference between groups but there is no 
clear correlation with the clinical characteristics of the 
subjects. Conclusion: Isoprostane may not serve as 
a marker for early detection of diabetes. However, its 
value may predict the oxidative status of the subjects 
and hence the development of the complications 
associated with diabetes.
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the most challenging health problems faced by many 
developing and industrialized countries.[1] The cause of 
type 2 diabetes mellitus (T2DM) is insulin resistance 
and relative insulinopenia.[2] One of the foremost 
challenges we face is to account mechanistically 
for the myriad other biochemical and physiological 
abnormalities characteristic of this disease. These 
abnormalities include central obesity, hypertension, 
accelerated atherosclerosis, hypertriglyceridemia 
and low serum concentrations of high density 
lipoproteins.[3,4]
Isoprostanes, a new class of biologically active products 
of arachidonic acid metabolism, are emerging as 
potentially relevant to human vascular disease. Besides 
providing a likely index of lipid peroxidation in this 
setting, measurements of specific F2-isoprostanes in 
urine may provide a sensitive biochemical end-point 
for dose-finding studies of natural and synthetic 
inhibitors of lipid peroxidation. F2-isoprostanes are 
prostaglandin like compounds formed in vivo from 
free radical catalyzed peroxidation of arachidonic 
acid, via a non-cyclooxygenase dependent mechanism. 
F2-isoprostanes are found in the body tissues in 
the esterified form, and in biological fluids such 
as plasma and urine in the free form.[5] Enhanced 
formation of F2-isoprostanes has been associated 
with several cardiovascular risk factors including 
hypertriglyceridemia[6] and diabetes mellitus[7] that 
are characterized by increasing lipid peroxidation and 
i n  response to  ot her  abnor mal it ies  suc h as 
atherosclerosis.[8] Among the 15 series of isoprostanes, 
F2-isoprostanes possess more marked biological functions 
such as vasoconstriction, stimulating mitogenesis, 
enhancing monocytes and polymorphonuclear cell 
adhesion to endothelial cells and inducing endothelial 
cell necrosis. This led us to focus our interest on 
F2-isoprostanes rather than other isoprostanes.
Introduction
Diabetes is one of the most common non-communicable 
diseases globally. It is either the fourth or fifth leading 
cause of death in most developed countries. It is one of 
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Impaired glucose tolerance (IGT) which can be assessed 
by oral glucose tolerance test is widely accepted as an 
entity of the prediabetic stage. It is commonly believed 
that IGT represents a transitional stage between normal 
glucose tolerance (NGT) and diabetes. Moreover, IGT 
is also a risk factor for cardiovascular disease either 
by itself or as a consequence of its presumed precursor 
relation to diabetes.[9] However, IGT is not a homogenous 
condition and only some of the subjects in transitional 
stage reach frank diabetes. Therefore, it is important to 
identify a more reliable marker for identifying people at 
high risk for diabetic complications.
This study was undertaken to (a) investigate the 
usefulness of F2-isoprostane as an oxidative biomarker 
in T2DM, (b) estimate the levels of F2-isoprostane among 
diabetics and (c) measure F2-isoprostane levels in IGT 
subjects as an early marker. The study was conducted 
among three groups of subjects: diabetic, NGT and IGT.
Materials and Methods
Subjects
The study included 25 diabetic, 25 NGT and 25 IGT 
subjects. The diabetics were those who have been 
diagnosed earlier and are currently on medication. The 
subjects were classified as having NGT if their fasting 
plasma glucose levels were less than 6 mmol/L and the 
2-hour plasma glucose loads values were less than 7.8 
mmol/L.[10]
Anthropometric measurements
Anthropometric measurements like weight and height 
were obtained using standardized techniques as 
detailed elsewhere.[11] Height was measured with a tape 
to the nearest centimeter. Weight was measured with 
a traditional spring balance that was kept on a firm 
horizontal surface. The body mass index (BMI) was 
calculated from the weight and height.
Laboratory studies
After an overnight fast, venous blood samples were 
drawn from each patient in sterile ethylenediamine 
tetraacetic acid (EDTA) tubes. Samples were assayed for 
plasma glucose, HbA1c, total cholesterol, triglycerides 
and high density lipoprotein (HDL) and low density 
lipoprotein (LDL) cholesterol.
Measurement of isoprostane
Five hundred microliters of serum was acidified to 
pH 3.5 with 100 µL of hydrochloric acid (12.1 M) and 
allowed to equilibrate at 4°C for 15 minutes. It was 
then centrifuged at 14,000 rpm for 5 minutes and 
applied to C18 cartridges (IST, Mid Glamorgan, UK) 
which had been preconditioned with 5 mL of ethanol 
and 5 mL of deionized water. The cartridges were 
subsequently washed with 5 mL of 15% ethanol and 
hexane (Merck, San Diego, CA, USA) under slight 
positive pressure to obtain a flow rate of 0.5 mL/minute. 
Isoprostanes were eluted from the column with 5 
mL of ethyl acetate (Schaelau, Barcelona, Spain) and 
stored at −70°C. Elutes were then evaporated under 
a stream of nitrogen and reconstituted in 230 µL of 
assay buffer. F2-isoprostane in elute was quantified 
using competitive immunoassay according to the 
manufacturer’s instructions (Assay Design, Ann Arbor, 
MI, USA). F2-isoprostane standards included in the kit 
were used within 60 minutes of preparation. Elutes and 
standards were pipetted into a microtiter plate coated 
with goat anti-rabbit immunoglobulins. Exactly 50 µL 
of alkaline phosphate conjugated with F2-isoprostane 
antibody (rabbit polyclonal antibody to F2-isoprostane) 
was added and incubated at room temperature on 
a shaker for 2 hours at 500 rpm. Wells were washed 
twice with the assay buffer before the substrate (P-nitro 
phenyl phosphate) was added and incubated further for 
45 minutes without shaking. Finally, enzyme reactions 
were stopped by the addition of 50 µL of trisodium 
phosphate and the optical density was read at 405 nm 
using a microplate reader.
Statistical analysis
Experimental data were expressed as mean ± SD. 
Statistical analysis was performed by using non-
parametric (Kruskal-Wallis) one-way analysis of 
variance (ANOVA) followed by Dunn’s test. A P value of 
less than 0.0001 was considered statistically significant 
between the groups. Statistical calculations were carried 
out using Graphpad Prism, version 5.0 (Graph Pad 
Software Inc., Los Angeles, San Diego, California, USA).
Results
A total of 75 subjects, grouped according to those with 
NGT (control, n = 25), IGT (n = 25) and established 
diabetes (T2DM, n = 25) were studied. The clinical and 
biochemical profiles of the study subjects are shown in 
Table 1. There were no significant differences between 
the groups IGT and NGT, but age, BMI, fasting plasma 
glucose, HbA1c, total cholesterol, triglycerides, LDL 
cholesterol were significantly higher among subjects 
with T2DM compared to subjects with NGT and IGT (P 
< 0.0001). Plasma concentration of total F2-isoprostane 
in subjects with T2DM and IGT had significantly 
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higher mean values compared with that of NGT group 
(P < 0.0001) [Figure 1].
Discussion
This study evaluates whether F2-isoprostane is an early 
marker for development of diabetes or IGT. IGT is the 
intermediate state which exists between NGT and the 
overt diabetes.[11-15] Insulin resistance and impaired 
β-cell function are the primary defects observed in 
T2DM, which can be detected in subjects with IGT. 
However, clinical studies suggest that the site of insulin 
resistance varies between these two disorders. Subjects 
with IGT have marked muscle insulin resistance with 
only mild hepatic insulin resistance. Impairment of 
insulin secretion in individuals with IGT remains 
controversial because both lower and normal early 
and late insulin secretory responses have been 
reported.[15-17] Likewise, in our study, patients with IGT 
had lower fasting glucose levels than patients with T2DM 
suggesting the late-phase of onset of diabetes. This study 
is of significance as this is the first report in Malaysian 
population on the association of F2-isoprostane levels 
with IGT, particularly in prediabetic subjects. Il’yasova 
et al,[18] showed in a case–control study that there exists 
no longitudinal association of isoprostanes levels [as 
measured by gas chromatography–mass spectrometry 
(GC–MS)] in 26 cases of incident T2DM, but they did not 
investigate subjects with IGT. It may be that isoprostanes 
are biologically insufficient to independently induce 
hyperglycemia, or alternatively, a larger sample that 
may have more power to discriminate between the 
glycemic groups may be needed. A negative correlation 
between F2-isoprostanes, clinical characteristics and the 
progression to IGT or T2DM implies that F2-isoprostanes 
might be involved in the development of complications 
of diabetes but not in the onset. Unlike other reports, 
isoprostanes in our population did not serve as valuable 
markers for the early onset of diabetes.
In conclusion, our findings do not support the hypothesis 
that isoprostane is a good marker for early onset of 
diabetes. Further studies on genetic profile of these 
populations may reveal a clearer delineation. However, 
F2-isoprostanes may be good markers for the development 
of cardiovascular complications of diabetes[4] and are 
correlated with hypercholesterolemia.[5]
References
1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of 
diabetes and its complications: Estimates and projections to the 
year 2010. Diabet Med 1997;14:S1-85.
2. Hjelmesaeth J, Asberg A, Muller F, Hartmann A, Jenssen T. New-
onset posttransplantation diabetes mellitus: Insulin resistance 
or insulinopenia? Impact of immunosuppressive drugs, 
cytomegalovirus and hepatitis C virus infection. Curr Diabetes 
Rev 2005;1:1-10.
3. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: 
The Framingham study. Circulation 1979;59:8-13.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality 
from coronary heart disease in subjects with type 2 diabetes and in 
nondiabetic subjects with and without prior myocardial infarction. 
N Engl J Med 1998;339:229-34.
5. Pratico D. F2-isoprostanes: Sensitivity and specific non-invasive 
indices of lipid peroxidation in vivo. Atherosclerosis 1999;147:1-10.
6. Reilly MP, Pratico D, Delanty N, DiMinno G, Tremoli E, Rader 
D, et al. Increased formation of distinct F2-isoprostanes in 
hypercholesterolemia. Circulation 1998;98:2822-8.
7. Gopaul NK, Anggard EE, Mallet AI, Betteridge DJ, Wolff SP, 
Nourooz-Zadeh J. Plasma 8-epi-PGF2 alpha levels are elevated in 
individuals with non-insulin dependent diabetes mellitus. FEBS 
Lett 1995;368:225-9.
8. Witztum JL, Berliner JA. Oxidized phospholipids and isoprostanes 
in atherosclerosis. Curr Opin Lipidol 1998;9:441-8.
9. Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, 
Freymond D, et al. Impaired glucose tolerance as a disorder of 
Table 1: Clinical characteristics of study subjects
NGT (n = 25) IGT (n = 25) T2DM (n = 25)
Age, years 35.8 ± 3.41 39 ± 5.02 58 ± 5.77**#
BMI, kg/m2 24.0 ± 2.35 27.3 ± 2.58 28.6 ± 4.94**
Fasting plasma 
glucose (mmol/L)
4.76 ± 0.572 5.29 ± 0.807 11.0 ± 1.37**#
HbA1c (%) 5.53 ± 0.337 6.03 ± 0.687 11.0 ± 0.67**#
Total cholesterol 
(mmol/L)
4.81 ± 0.55 4.93 ± 0.72 7.19 ± 0.56**#
Triglyceride 
(mmol/L)
1.79 ± 0.53 1.95 ± 0.64 4.13 ± 0.57**#
HDL cholesterol 
(mmol/L)
1.87 ± 0.26 1.78 ± 0.31 1.03 ± 0.13**#
LDL cholesterol 
(mmol/L)
2.63 ± 0.51 2.76 ± 0.65 3.99 ± 0.63**#
Data are expressed as mean ± SD; **P < 0.0001 as compared to NGT; 
#P < 0.0001 as compared to IGT
Figure 1: Plasma F2-isoprostane levels among subjects with NGT, IGT and T2DM
Kaviarasan, et al.: F2-isoprostane as a biological marker of diabetes
170 Int J Diab Dev Ctries | July-September 2010 | Volume 30 | Issue 3
insulin action. Longitudinal and cross-sectional studies in Pima 
Indians. N Engl J Med 1988;318:1217-25.
10. Alberti KG, Zimmet PZ. Definition, diagnosis and classification 
of diabetes mellitus and its complications. Part 1: Diagnosis and 
classification of diabetes mellitus provisional report of a WHO 
consultation. Diabet Med 1998;15:539-53.
11. Report of the Expert Committee on the Diagnosis and Classification 
of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
12. Classification and diagnosis of diabetes mellitus and other 
categories of glucose intolerance. National Diabetes Data Group. 
Diabetes 1979;28:1039–57.
13. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron 
AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired 
glucose tolerance: The Australian Diabetes, Obesity and Lifestyle 
Study. Diabetes Care 2002;25:829-34.
14. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE; American 
Diabetes Association GENNID Study Group. Beta-cell function is 
a major contributor to oral glucose tolerance in high-risk relatives 
of four ethnic groups in the U.S. Diabetes 2002;51:2170-8.
15. Perry IJ, Wannamethee SG, Walker MK, Thomson AG, Whincup 
PH, Shaper AG. Prospective study of risk factors for development 
of non-insulin dependent diabetes in middle aged British men. 
BMJ 1995;310:560-4.
16. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of 
beta-cell dysfunction and insulin resistance to the pathogenesis of 
impaired glucose tolerance and impaired fasting glucose. Diabetes 
Care 2006;29:1130-9.
17. Davies MJ, Raymond NT, Day JL, Hales CN, Burden AC. Impaired 
glucose tolerance and fasting hyperglycaemia have different 
characteristics. Diabet Med 2000;17:433-40.
18. Il'yasova D, Morrow JD, Wagenknecht LE. Urinary F2-isoprostanes 
are not associated with increased risk of type 2 diabetes. Obes Res 
2005;13:1638-44.
Source of Support: Nil, Conflict of Interest: None declared
Kaviarasan, et al.: F2-isoprostane as a biological marker of diabetes
